TIDMKNB

RNS Number : 4820Y

Kanabo Group PLC

04 May 2023

4 May 2023

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

Board Change

Kanabo Group Plc (LSE: KNB), the patient focused healthcare technology and medicinal cannabis company, announces the appointment of Sharon Malka as Non-Executive Director ("NED") with immediate effect.

The Company also announces that Gil Efron will step down from his position as a Non-Executive Director with immediate effect, in order to focus on his rehabilitation following a recent accident. Sharon Malka will assume the role of Chair of the Audit Committee following Gil's departure.

Sharon Malka brings a wealth of experience to Kanabo, having held senior leadership positions with a number of international healthcare and technology companies. Sharon Malka is currently Chief Executive Officer of Dotz Nano Ltd. ("Dotz"), an Australian-based technology company focused on developing, manufacturing and commercialising advanced materials for diagnostics solutions. In addition to his position at Dotz, Sharon Malka has spent the past 16 years at MediWound Limited, a Nasdaq-listed biopharmaceutical company. Sharon is a member of MediWound Limited's Board of Directors, and he has previously been MediWound Limited's Chief Financial Officer and Chief Executive Officer. Previously, Sharon held the role of Partner at Variance Economic Consulting Ltd., a financial services consulting boutique focused on international technology companies, and served as a Senior Manager position for PwC Corporate Finance.

Sharon Malka is a qualified accountant and holds a B.Sc. in Business Administration from the Business Management College in Israel and an M.B.A. from Bar Ilan University, Israel.

David Tsur, Deputy Chair of Kanabo, commented:

"We would like to thank Gil for his significant contribution, dedication and commitment to Kanabo and we hope he makes a full and speedy recovery.

"On behalf of the Board, I would like to welcome Sharon to Kanabo. He brings a wealth of experience in innovative technology companies and capital markets. We look forward to benefitting from his knowledge and expertise as we continue to focus on expanding the service offering and market reach for Kanabo services and products."

Save for the information disclosed below, Kanabo confirms there is no further information to be disclosed under the requirements of Listing Rule 9.6.13 in relation to the appointment of Sharon Malka as Non-Executive Director.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 
 Current Directorships     Non-current directorships (past 
                            5 years) 
 Dotz Nano Ltd.            MediWound UK Limited 
  MediWound Limited

Enquiries:

 
Kanabo Group plc                                       via Vigo Consulting 
 Avihu Tamir, Chief Executive Officer                   +44 (0)20 7390 0230 
 Assaf Vardimon, Chief Financial Officer 
Peterhouse Capital Ltd (Financial Adviser) 
 Eran Zucker                                           +44 (0)20 7469 0930 
 
Vigo Consulting (Financial Public Relations/Investor 
 Relations) 
 Jeremy Garcia / Fiona Hetherington / Verity 
 Snow                                                   +44 (0)20 7390 
 kanabo@vigoconsulting.com                               0230

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUPUAWAUPWGAC

(END) Dow Jones Newswires

May 04, 2023 11:45 ET (15:45 GMT)

Spinnaker Opportunities (LSE:SOP)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Spinnaker Opportunities Charts.
Spinnaker Opportunities (LSE:SOP)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Spinnaker Opportunities Charts.